TigerOak Management L.L.C. bought a new position in shares of Danaher Co. (NYSE:DHR – Free Report) during the fourth quarter, Holdings Channel reports. The firm bought 5,446 shares of the conglomerate’s stock, valued at approximately $1,250,000.
A number of other hedge funds also recently made changes to their positions in DHR. Congress Asset Management Co. raised its stake in Danaher by 629.0% in the 4th quarter. Congress Asset Management Co. now owns 7,516 shares of the conglomerate’s stock valued at $1,725,000 after acquiring an additional 6,485 shares during the period. Roxbury Financial LLC bought a new stake in Danaher in the 4th quarter valued at about $42,000. Manchester Capital Management LLC raised its stake in Danaher by 2.6% in the 4th quarter. Manchester Capital Management LLC now owns 4,515 shares of the conglomerate’s stock valued at $1,037,000 after acquiring an additional 113 shares during the period. Accretive Wealth Partners LLC raised its stake in Danaher by 3.5% in the 4th quarter. Accretive Wealth Partners LLC now owns 3,804 shares of the conglomerate’s stock valued at $873,000 after acquiring an additional 127 shares during the period. Finally, Empire Life Investments Inc. raised its stake in Danaher by 23.7% in the 4th quarter. Empire Life Investments Inc. now owns 77,686 shares of the conglomerate’s stock valued at $17,833,000 after acquiring an additional 14,897 shares during the period. 79.05% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In related news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 11.10% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
Get Our Latest Analysis on DHR
Danaher Price Performance
DHR stock opened at $206.66 on Friday. The firm has a market cap of $149.26 billion, a P/E ratio of 39.14, a P/E/G ratio of 2.68 and a beta of 0.83. The firm’s fifty day moving average is $229.53 and its 200 day moving average is $249.51. Danaher Co. has a 52 week low of $196.80 and a 52 week high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40.
Danaher (NYSE:DHR – Get Free Report) last issued its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period in the previous year, the firm posted $2.09 EPS. Research analysts predict that Danaher Co. will post 7.67 earnings per share for the current year.
Danaher Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.52%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s payout ratio is presently 20.45%.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
See Also
- Five stocks we like better than Danaher
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- What is a Dividend King?
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- Canadian Penny Stocks: Can They Make You Rich?
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.